AC Immune SA (ACIU)
After hours:
| Previous close | 5.0200 |
| Open | 5.0700 |
| Bid | 4.8000 x 800 |
| Ask | 4.8900 x 800 |
| Day's range | 4.7800 - 5.0700 |
| 52-week range | 4.7800 - 12.6100 |
| Volume | |
| Avg. volume | 531,336 |
| Market cap | 352.366M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage development LAUSANNE, Switzerland, Nov. 12, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today presented new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti-phosph
- Globe Newswire
AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer’s Disease
Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rate of cognitive decline vs. placebo Benefit of semorinemab on ADAS-Cog11 in all prespecified subgroups was consistent with the treatment effect in the overall cohort, regardless of disease severity, baseline Tau load, and ApoE carrier status Benefit on cognition was driven primarily by the memory d
- Globe Newswire
AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer’s disease Closed its strategic acquisition of an industry-leading Parkinson’s disease vaccine and an equity financing led by key investors Appointed Monica Shaw, M.D., and Prof. Monika Bütler, Dr. Oec., to the Board of Directors Strong financial position of CHF 188.6 million1 ensures the Company is fully financed through at least Q1 2024 LAUSANNE, Switzerland, Nov. 08, 2021 (GLOBE
